Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANK-301
- Development stage
- Preclinical
- Lead developer
- Ankyra Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
ANK-301 is a dual-targeting bi-agonist being developed by Ankyra Therapeutics for the treatment of solid tumors. It is designed to simultaneously engage CD40 and deliver Interleukin-2 (IL-2) signaling to the tumor microenvironment. By targeting CD40, the drug aims to activate antigen-presenting cells (APCs) and enhance T-cell priming, while the IL-2 component promotes the expansion and effector function of cytotoxic T cells and natural killer (NK) cells. This synergistic approach is intended to overcome immune suppression and drive robust anti-tumor immune responses. The molecule is part of Ankyra's platform designed for localized, anchored delivery to minimize systemic toxicity while maximizing local therapeutic effect. As of early 2024, the program is in the discovery stage.
- Other names
- CD40-IL-2 bi-agonistCD-40-IL-2 bi-agonistCD 40-IL-2 bi-agonist
02
Targets
CD40 (Cluster of differentiation 40 receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on ANK-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANK-301.